Head to Head Review: Omnicell Technologies (OMCL) & Capcom (CCOEY)

Omnicell Technologies (NASDAQ: OMCL) and Capcom (OTCMKTS:CCOEY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.

Risk & Volatility

How to Become a New Pot Stock Millionaire

Omnicell Technologies has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Capcom has a beta of -5.34, indicating that its stock price is 634% less volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Capcom shares are held by institutional investors. 3.7% of Omnicell Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Omnicell Technologies and Capcom’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Omnicell Technologies $716.16 million 2.38 $20.60 million $0.18 243.89
Capcom $806.32 million 5.64 $79.27 million $0.37 45.41

Capcom has higher revenue and earnings than Omnicell Technologies. Capcom is trading at a lower price-to-earnings ratio than Omnicell Technologies, indicating that it is currently the more affordable of the two stocks.


Capcom pays an annual dividend of $0.04 per share and has a dividend yield of 0.2%. Omnicell Technologies does not pay a dividend. Capcom pays out 10.8% of its earnings in the form of a dividend.

Analyst Ratings

This is a summary of current recommendations and price targets for Omnicell Technologies and Capcom, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omnicell Technologies 0 2 5 0 2.71
Capcom 0 1 0 0 2.00

Omnicell Technologies presently has a consensus target price of $56.14, suggesting a potential upside of 27.89%. Capcom has a consensus target price of $17.84, suggesting a potential upside of 6.19%. Given Omnicell Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Omnicell Technologies is more favorable than Capcom.


This table compares Omnicell Technologies and Capcom’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Omnicell Technologies 2.88% 1.54% 0.77%
Capcom N/A N/A N/A


Omnicell Technologies beats Capcom on 10 of the 16 factors compared between the two stocks.

About Omnicell Technologies

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

About Capcom

Capcom Co., Ltd. plans, develops, manufactures, sells, and distributes home video games, online games, mobile games, and arcade games in Japan and internationally. It operates through Digital Contents, Arcade Operations, Amusement Equipments, and Other Businesses segments. The Digital Contents segment develops and sells package games and digital download content. This segment also develops and manages mobile contents and PC online games. The Arcade Operations segment operates “Plaza Capcom” amusement facilities in commercial complexes, and hosts various events. The Amusement Equipments segment is involved in the development, manufacture, and sale of frames and LCD devices for gaming machines, as well as software; and development, production, and sale of arcade games for amusement facilities. The Other Businesses segment publishes walkthrough and strategy guides, as well as game settings collections; licenses music CDs and licensed merchandise; and develops game content into movie and TV animation programs. The company was founded in 1979 and is headquartered in Osaka, Japan.

Receive News & Ratings for Omnicell Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply